{
    "2018-08-13": [
        [
            {
                "time": "2018-01-02",
                "original_text": "XBIO To Report Phase 2 Data This Year, VNRX Abuzz, ATRS To Face FDA In Sep",
                "features": {
                    "keywords": [
                        "Phase 2 Data",
                        "VNRX Abuzz",
                        "ATRS FDA"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Shire, Shionogi File NDA for Intuniv for Adults in Japan",
                "features": {
                    "keywords": [
                        "Shire",
                        "Shionogi",
                        "NDA",
                        "Intuniv",
                        "Japan"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses",
                "features": {
                    "keywords": [
                        "Ionis Pharmaceuticals",
                        "Royalties",
                        "Expenses"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "How GlaxoSmithKline’s Segments Have Performed",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "Segments",
                        "Performance"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "How GlaxoSmithKline’s Valuation Compares with Peers’",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "Valuation",
                        "Peers"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades",
                "features": {
                    "keywords": [
                        "CAH",
                        "SAFE Dividend",
                        "Increasing Payments"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Ex-Dividend",
                        "Date Scheduled"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}